Viatris (VTRS) Enterprise Value (2019 - 2026)
Viatris' (VTRS) quarterly Enterprise Value came in at -$1.8 billion in Q1 2026, down 138.97% year-on-year from $4.6 billion in Q1 2025, and down 36.43% quarter-over-quarter from -$1.3 billion in Q4 2025.
Viatris (VTRS) Enterprise Value (2019 - 2026) Analysis & Trends
Viatris' Enterprise Value history runs 8 years deep, the most recent figure standing at -$1.8 billion for Q1 2026.
- On a quarterly basis, Enterprise Value fell 138.97% year-over-year to -$1.8 billion in Q1 2026; TTM through Mar 2026 was -$1.8 billion, a 138.97% decrease from a year earlier, with the FY2025 full-year figure at -$1.3 billion, down 79.65% from the prior year.
- Enterprise Value declined to -$1.8 billion in Q1 2026 per VTRS's latest filing, from -$1.3 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$506.6 million in Q1 2023 and bottomed at -$1.9 billion in Q3 2024.
- The 5-year median for Enterprise Value is -$917.2 million (2024), against an average of -$984.3 million.
- Across the five-year window, Enterprise Value surged 48.09% in 2025 and slumped 138.97% in 2026, its largest moves.
- Year by year, Enterprise Value stood at -$1.3 billion in 2022, then increased by 21.43% to -$991.9 million in 2023, then gained by 25.79% to -$736.1 million in 2024, then tumbled by 79.65% to -$1.3 billion in 2025, then plunged by 36.43% to -$1.8 billion in 2026.
- Per Business Quant, the three latest VTRS Enterprise Value figures stand at -$1.8 billion (Q1 2026), -$1.3 billion (Q4 2025), and -$975.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | -1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | -3.74 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -4.05 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -2.15 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | -3.97 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -1.80 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | -1.32 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | -428.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -153.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.80 Bn |
| Dec 31, 2025 | -1.32 Bn |
| Sep 30, 2025 | -975.30 Mn |
| Jun 30, 2025 | -566.40 Mn |
| Mar 31, 2025 | -755.00 Mn |
| Dec 31, 2024 | -736.10 Mn |
| Sep 30, 2024 | -1.88 Bn |
| Jun 30, 2024 | -917.20 Mn |
| Mar 31, 2024 | -1.01 Bn |
| Dec 31, 2023 | -991.90 Mn |
| Sep 30, 2023 | -1.31 Bn |
| Jun 30, 2023 | -629.20 Mn |
| Mar 31, 2023 | -506.60 Mn |
| Dec 31, 2022 | -1.26 Bn |
| Sep 30, 2022 | -646.70 Mn |
| Jun 30, 2022 | -664.70 Mn |
| Mar 31, 2022 | -752.40 Mn |
| Dec 31, 2021 | -706.20 Mn |
| Sep 30, 2021 | -756.60 Mn |
| Jun 30, 2021 | -673.90 Mn |